EMR cumulative indigenous measles/rubella case counts and surveillance indicators
Between 01/01/2017 and 31/01/2017

|  | Measles case finding report |  |  |  |  |  |  | Rubella case finding report |  |  |  |  |  | Measl <br> es <br> incide <br> nce <br> $/ 1000$, <br> 000 <br> $*$ | Rubel <br> la <br> incide <br> nce <br> 11000, <br> 000 <br> $* *$ | Report ing rate *** | Indicators : target $\geq 80 \%$ |  |  |  |  | Last Date reported | Genotypes reported |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Country | Total <br> suspecte <br> $d$ cases <br> for $M / R$ | ```specimen s tested for measles``` | Measles Lab confirm ed | Measles EpiLinked | Measles clinically compatib le | $\begin{array}{\|c\|} \hline \text { Total } \\ \text { measle } \end{array}$ | Measles discarde d cases | $\begin{gathered} \text { specim } \\ \text { ens } \\ \text { tested } \\ \text { for } \\ \text { rubella } \end{gathered}$ | Rubell a lab confir med | $\begin{array}{\|l\|} \hline \text { Rube } \\ \text { lla } \\ \text { Epi- } \\ \text { Link } \\ \text { ed } \end{array}$ | Rube <br> Ila <br> clinic <br> ally | $\begin{gathered} \hline \text { Total } \\ \text { Rubell } \\ \text { a } \end{gathered}$ | Rubella discarde d cases |  |  |  | ```suspects tested for measles ****``` | cases with complete investigati on | specimens recieved at the lab within 5days | specime ns with adequat e condition | $\begin{array}{\|c\|} \hline \text { results } \\ \text { reported } \\ \text { back } \\ \text { within } \\ \text { 4days } \end{array}$ |  |  |
| Afghanistan | 304 | 304 | 225 | 0 | 0 | 225 | 79 | 77 | 8 | 0 | 0 | 8 | 69 | 6.97 | 0.25 | 0.22 | 100\% |  | 47\% | 99\% | 99\% | 31/01/2017 |  |
| Bahrain | 30 | 30 | 0 | 0 | 0 | 0 | 30 | 30 | 0 | 0 | 0 | 0 | 30 | 0.00 | 0.00 | 2.43 | 100\% | 100\% | 100\% | 100\% | 100\% | 31/01/2017 |  |
| Iran | 716 | 606 | 0 | 0 | 1 | 1 | 715 | 606 | 0 | 0 | 0 | 0 | 606 | 0.01 | 0.00 | 0.91 | 85\% | 100\% | 82\% | 100\% | 93\% | 31/01/2017 |  |
| Iraq | 24 | 23 | 0 | 0 | 0 | 0 | 24 | 23 | 1 | 0 | 0 | 1 | 22 | 0.00 | 0.03 | 0.07 | 96\% | 75\% | 88\% | 100\% | 96\% | 29/01/2017 |  |
| Egypt | 260 | 200 | 4 | 0 | 0 | 4 | 256 | 202 | 4 | 0 | 0 | 4 | 198 | 0.04 | 0.04 | 0.28 | 77\% | 74\% | 90\% | 100\% | 99\% | 21/01/2017 |  |
| Lebanon | 7 | 5 | 3 | 0 | 2 | 5 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 0.87 | 0.00 | 0.03 | 71\% | 100\% | 40\% | 100\% | 100\% | 29/01/2017 |  |
| Morocco | 15 | 15 | 0 | 0 | 0 | 0 | 15 | 13 | 0 | 0 | 0 | 0 | 13 | 0.00 | 0.00 | 0.05 | 100\% | 100\% | 85\% | 100\% | 87\% | 29/01/2017 |  |
| Pakistan | 572 | 572 | 365 | 0 | 0 | 365 | 207 | 572 | 0 | 0 | 0 | 0 | 572 | 2.06 | 0.00 | 0.12 | 100\% |  | 77\% | 100\% | 74\% | 30/01/2017 |  |
| Palestine | 4 | 4 | 0 | 0 | 0 | 0 | 4 | 4 | 0 | 0 | 0 | 0 | 4 | 0.00 | 0.00 | 0.10 | 100\% | 100\% | 75\% | 100\% | 100\% | 28/01/2017 |  |
| Saudi Arabia | 154 | 154 | 75 | 0 | 0 | 75 | 79 | 154 | 2 | 0 | 0 | 2 | 152 | 2.64 | 0.07 | 0.27 | 100\% | 50\% | 100\% | 100\% | 99\% | 31/01/2017 |  |
| Sudan | 247 | 198 | 30 | 47 | 0 | 77 | 170 | 198 | 43 | 0 | 0 | 43 | 155 | 1.87 | 1.04 | 0.31 | 99\% | 100\% | 86\% | 99\% | 94\% | 31/01/2017 |  |
| Syria | 51 | 50 | 24 | 1 | 0 | 25 | 26 | 42 | 0 | 0 | 0 | 0 | 42 | 1.12 | 0.00 | 0.12 | 100\% | 100\% | 88\% | 90\% | 90\% | 31/01/2017 |  |
| Tunisia | 11 | 10 | 0 | 0 | 0 | 0 | 11 | 11 | 1 | 0 | 0 | 1 | 10 | 0.00 | 0.09 | 0.09 | 91\% | 82\% | 45\% | 100\% | 82\% | 30/01/2017 |  |
| UAE | 46 | 41 | 8 | 0 | 4 | 12 | 34 | 36 | 1 | 0 | 1 | 2 | 34 | 1.31 | 0.11 | 0.36 | 89\% | 65\% | 95\% | 100\% | 78\% | 31/01/2017 |  |
| Yemen | 353 | 3 | 2 | 3 | 0 | 5 | 348 | 3 | 0 | 0 | 0 | 0 | 3 | 0.18 | 0.00 | 1.25 | 1\% | 89\% | 74\% | 98\% | 1\% | 31/01/2017 |  |
| Total EMR | 2794 | 2215 | 736 | 51 | 7 | 794 | 2000 | 1972 | 60 | 0 | 1 | 61 | 1911 | 1.28 | 0.10 | 0.31 | 81\% | 76\% | 78\% | 99\% | 86\% |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Countries that did not report
Djibouti, Kuwait, Libya, Oman and Qatar

Countries that reported zero suspect case Jordan, Somalia

Yemen reported low testing cases due to shortage of $M / R$ kits

## Measles final classification and distribution by Month

Between 01/01/2017 and 31/01/2017

| Country | Total <br> Suspected <br> cases for <br> measles | Total <br> specimen <br> s tested | Measlesi <br> mported <br> cases * | MeaslesI <br> mport <br> related* <br> $*$ | Vaccine <br> related <br> $* * *$ |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Afghanistan | 304 | 304 | 0 | 0 | 0 |
| Bahrain | 30 | 30 | 0 | 0 | 1 |
| Iran | 716 | 606 | 1 | 8 | 15 |
| Iraq | 24 | 23 | 0 | 0 | 0 |
| Egypt | 260 | 200 | 0 | 0 | 0 |
| Lebanon | 7 | 5 | 0 | 0 | 0 |
| Morocco | 15 | 15 | 0 | 0 | 0 |
| Pakistan | 572 | 572 | 0 | 0 | 0 |
| Palestine | 4 | 4 | 0 | 0 | 0 |
| Saudi Arabia | 154 | 154 | 0 | 0 | 0 |
| Sudan | 247 | 198 | 0 | 0 | 0 |
| Syria | 51 | 50 | 0 | 0 | 2 |
| Tunisia | 11 | 10 | 0 | 0 | 0 |
| UAE | 46 | 41 | 0 | 0 | 0 |
| Yemen | 353 | 3 | 0 | 0 | 0 |
| Total | $\mathbf{2 7 9 4}$ | $\mathbf{2 2 1 5}$ | $\mathbf{1}$ | $\mathbf{8}$ | $\mathbf{1 8}$ |


| Measles lab confirme d | Measles EpiLinked | Measles clinically comp. | Total confirme d cases \# | Jan | Feb | Mar | April | May | June | July | Aug | Sept | Oct | Nov | Dec |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 225 | 0 | 0 | 225 | 225 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 0 | 0 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | 0 | 2 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 365 | 0 | 0 | 365 | 365 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 75 | 0 | 0 | 75 | 75 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 30 | 47 | 0 | 77 | 77 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 24 | 1 | 0 | 25 | 25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | 0 | 4 | 12 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 3 | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 736 | 51 | 7 | 794 | 794 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

[^0]
## Geographic distribution of Measles cases in the EMR countries January 2017



Rubella final classification and distribution by Month
Between 01/01/2017 and 31/01/2017

| Country | Total <br> Suspected <br> cases for <br> rubella | Total <br> specimen <br> s tested | Rubella <br> importe <br> $\mathbf{d}^{*}$ | Rubellai <br> mport <br> related <br> $* *$ | Rubella <br> vaccine <br> related* <br> $* *$ |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Afghanistan | 304 | 77 | 0 | 0 | 0 |
| Bahrain | 30 | 30 | 0 | 0 | 1 |
| Iran | 716 | 606 | 0 | 0 | 15 |
| Iraq | 24 | 23 | 0 | 0 | 0 |
| Egypt | 260 | 202 | 0 | 0 | 0 |
| Lebanon | 7 | 1 | 0 | 0 | 0 |
| Morocco | 15 | 13 | 0 | 0 | 0 |
| Pakistan | 572 | 572 | 0 | 0 | 0 |
| Palestine | 4 | 4 | 0 | 0 | 0 |
| Saudi Arabia | 154 | 154 | 0 | 0 | 0 |
| Sudan | 247 | 198 | 0 | 0 | 0 |
| Syria | 51 | 42 | 0 | 0 | 2 |
| Tunisia | 11 | 11 | 0 | 0 | 0 |
| UAE | 46 | 36 | 0 | 0 | 0 |
| Yemen | 353 | 3 | 0 | 0 | 0 |
| Total | 2794 | 1972 | 0 | 0 | 18 |


| Rubella lab confirme d | Rubella EpiLinked | Rubella clinically comp. | Total confirme d cases \# | Jan | Feb | Mar | April | May | June | July | Aug | Sept | Oct | Nov | Dec |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 8 | 0 | 0 | 8 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 0 | 0 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 43 | 0 | 0 | 43 | 43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 60 | 0 | 1 | 61 | 61 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

[^1]Geographic distribution of Rubella cases in the EMR countries January 2017


Measles and Rubella laboratory summary report
Between 01/01/2017 and 31/01/2017

| Country | Total Suspected cases M/R | Measles |  |  |  |  |  |  |  | Rubella |  |  |  |  |  |  |  | Reporte d to EPI within 4days |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | specimens tested | \% | Positive | \% | Negative | \% | Equivocal | \% | specimens tested | \% | Positive | \% | Negative | \% | Equivocal | \% |  |
| Afghanistan | 304 | 304 | 100\% | 227 | 75\% | 77 | 25\% | 0 | 0\% | 77 | 25\% | 8 | 10\% | 69 | 90\% | 0 | 0\% | 99\% |
| Bahrain | 30 | 30 | 100\% | 0 | 0\% | 30 | 100\% | 0 | 0\% | 30 | 100\% | 0 | 0\% | 30 | 100\% | 0 | 0\% | 100\% |
| Iran | 716 | 606 | 85\% | 25 | 4\% | 581 | 96\% | 0 | 0\% | 606 | 85\% | 4 | 1\% | 602 | 99\% | 0 | 0\% | 93\% |
| Iraq | 24 | 23 | 96\% | 0 | 0\% | 23 | 100\% | 0 | 0\% | 23 | 96\% | 1 | 4\% | 22 | 96\% | 0 | 0\% | 96\% |
| Egypt | 260 | 200 | 77\% | 4 | 2\% | 196 | 98\% | 0 | 0\% | 202 | 78\% | 6 | 3\% | 196 | 97\% | 0 | 0\% | 99\% |
| Lebanon | 7 | 5 | 71\% | 3 | 60\% | 2 | 40\% | 0 | 0\% | 1 | 14\% | 0 | 0\% | 1 | 100\% | 0 | 0\% | 100\% |
| Morocco | 15 | 15 | 100\% | 0 | 0\% | 15 | 100\% | 0 | 0\% | 13 | 87\% | 0 | 0\% | 13 | 100\% | 0 | 0\% | 87\% |
| Pakistan | 572 | 572 | 100\% | 365 | 64\% | 207 | 36\% | 0 | 0\% | 572 | 100\% | 0 | 0\% | 572 | 100\% | 0 | 0\% | 74\% |
| Palestine | 4 | 4 | 100\% | 0 | 0\% | 4 | 100\% | 0 | 0\% | 4 | 100\% | 0 | 0\% | 4 | 100\% | 0 | 0\% | 100\% |
| Saudi Arabia | 154 | 154 | 100\% | 75 | 49\% | 79 | 51\% | 0 | 0\% | 154 | 100\% | 2 | 1\% | 152 | 99\% | 0 | 0\% | 99\% |
| Sudan | 247 | 198 | 80\% | 30 | 15\% | 168 | 85\% | 0 | 0\% | 198 | 80\% | 43 | 22\% | 154 | 78\% | 1 | 1\% | 94\% |
| Syria | 51 | 50 | 98\% | 26 | 52\% | 24 | 48\% | 0 | 0\% | 42 | 82\% | 0 | 0\% | 40 | 95\% | 2 | 5\% | 90\% |
| Tunisia | 11 | 10 | 91\% | 1 | 10\% | 9 | 90\% | 0 | 0\% | 11 | 100\% | 2 | 18\% | 9 | 82\% | 0 | 0\% | 82\% |
| UAE | 46 | 41 | 89\% | 8 | 20\% | 33 | 80\% | 0 | 0\% | 36 | 78\% | 1 | 3\% | 35 | 97\% | 0 | 0\% | 78\% |
| Yemen | 353 | 3 | 1\% | 2 | 67\% | 1 | 33\% | 0 | 0\% | 3 | 1\% | 0 | 0\% | 3 | 100\% | 0 | 0\% | 1\% |
| Total | 2794 | 2215 | 79\% | 766 | 35\% | 1449 | 65\% | 0 | 0\% | 1972 | 71\% | 67 | 3\% | 1902 | 96\% | 3 | 0\% | 86\% |


[^0]:     the 12-23 days prior to rash onset)
    
     56 days after vaccination and there were no secondary cases identified. OR any suspect case from which virus is isolated and genotyping test reveals the virus to be a vaccine strain
    \# Total confirmed cases; include all cases confirmed by laboratory testing or epi linkage, plus those clinical cases that were reported without a laboratory specimen or epi linkage

[^1]:     the 12-23 days prior to rash onset)
    
     56 days after vaccination and there were no secondary cases identified. OR any suspect case from which virus is isolated and genotyping test reveals the virus to be a vaccine strain
    \# Total confirmed cases; include all cases confirmed by laboratory testing or epi linkage, plus those clinical cases that were reported without a laboratory specimen or epi linkage

